Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature by Marialuisa Appetecchia et al.
Appetecchia et al. BMC Endocrine Disorders 2014, 14:84
http://www.biomedcentral.com/1472-6823/14/84CASE REPORT Open AccessTesticular and inguinal lymph node metastases of
medullary thyroid cancer: a case report and
review of the literature
Marialuisa Appetecchia1*, Agnese Barnabei1, Vincenzo Pompeo2, Steno Sentinelli3, Roberto Baldelli1,
Salvatore Maria Corsello4 and Francesco Torino5Abstract
Background: The involvement of the testis by metastatic medullary thyroid carcinoma has never been described
before. We describe the first case of metastatic medullary thyroid carcinoma affecting testis and inguinal lymph
nodes.
Case presentation: A 73-year-old Caucasian man was referred to undergo urologic surgery due to a painless
nodule in the right testis and an homolateral inguinal lymphoadenomegaly. The patient had a history of medullary
thyroid carcinoma with relapsing disease to the spine and lung nodules. Serum calcitonin and CEA levels were
175 pg/ml and 22 ng/ml, respectively. With suspected testicular cancer, the patient underwent radical right
orchiectomy with the excision biopsy of the right inguinal lymph node. Histopathology and immunohistochemistry
revealed that both the lesions were due to metastases from medullary thyroid carcinoma.
Conclusion: Metastases to the testis and inguinal lymph nodes may be due to various solid and hematological
tumors. This case, despite its rarity, suggests that testis and inguinal lymph nodes should be considered as potential
secondary sites of medullary thyroid carcinoma as well.
Keywords: Medullary thyroid cancer, Testicular metastasis, Inguinal lymph node metastasisBackground
Medullary thyroid carcinoma (MTC) is a neuroendocrine
tumor that arises from the thyroid parafollicolar calcitonin
producing C cells and accounts for about 5% of thyroid
carcinomas [1]. MTC mainly presents as a sporadic
disease, but in approximately 20% of cases is hereditary.
Specific germline mutations in the rearranged during
transfection proto-oncogene (RET) have a pathogenic role
in the onset of familial MTC (FMTC) or MEN2, the two
clinical forms of hereditary MTC [2-4]. In these patients,
RET mutations predict prognosis and guide the choice of
treatment timing and follow-up. However, genetic testing
for germline RET mutations is recommended not only for
screening children and adults in known kindreds with* Correspondence: appetecchia@ifo.it
1Regina Elena National Cancer Institute, Endocrinology Unit, Via Elio Chianesi
53, I- 00144 Rome, Italy
Full list of author information is available at the end of the article
© 2014 Appetecchia et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.inherited forms of MTC, but also for all newly diagnosed
patients with clinically apparent sporadic MTC [1,2].
Sporadic MTC usually manifests in the fifth-sixth
decade, while familial forms have an earlier onset [1].
MTC usually presents as a palpable neck mass due to
thyroid nodule(s) and in 30-50% of cases it is accompanied
by metastases in cervical/paratracheal lymph nodes.
Upper and anterior mediastinal lymph nodes are also in
the pathway of tumor spread, but symptoms related to
aerodigestive tract compression/invasion are reported
by up to 15% of patients [5]. Distant metastases are
present at the diagnosis in 10-15% of patients. Preferred
sites of metastatic spread include lung, liver and bone [6].
Metastases to brain, adrenal glands, pleura, heart, ovary,
pancreas, pituitary, retina, skin and breast have been
rarely/exceptionally reported [7-9].
Compared with papillary/follicular thyroid cancer, MTC
is more aggressive having a higher rate of recurrence and
increased mortality [10]. Older age, larger tumor size,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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tastases correlate with worse prognosis as well as high
calcitonin and carcinoembrionic antigen (CEA) serum
levels [11]. The clinical course of advanced/metastatic
MTC is unpredictable. Lung or bone metastases may
initially cause symptoms in only 5-10% of patients.
Survival in patients with newly diagnosed distant
metastases is 51% at 1 year, 26% at 5 years and 10% at
10 years [10,12,13].
Surgery is the main treatment for primary MTC and
for local and distant metastases, whenever feasible.
External-beam radiation to the neck/upper mediastinum
is useful in patients with extrathyroidal disease or exten-
sive nodal metastases not undergoing curative resection
and for palliative purposes [2]. Cytotoxic chemotherapy is
used in patients with metastatic/unresectable MTC, but is
poorly effective [6]. Recently, vandetanib and cabozanti-
nib, two oral multikinase inhibitors improved survival in
patients with advanced/metastatic MTC and are licensed
for the treatment of these patients [14]. Several experi-
mental drugs, mainly kinase inhibitors, are under clinical
evaluation [15,16].
Herein, we report the case of a patient with MTC that
metastasized to the right testis and to an homolateral
inguinal lymph node, many years later to the detection
of skeletal and lung metastases.
Case presentation
In 2002, a 63 year old Caucasian man presenting a large
solitary nodule in the upper right lobe of thyroid was
cytologically diagnosed with medullary thyroid carcinoma
(MTC). No family history of MTC or multiple endocrine
neoplasia (MEN) was reported. Appropriate endocrine
work up excluded MEN2. Preoperative serum calcitonin
was 122 pg/ml (reference range: 0-9.6 pg/ml) with normal
carcinoembryonic antigen (CEA) serum levels. The pa-
tient underwent total thyroidectomy and bilateral neck
lymph node dissection. Histology confirmed a 52 mm in
diameter MTC confined to thyroid without metastases in
the 54 resected lymph nodes (stage III; UICC 2002). The
genetic testing identified the non-conservative functional
c.2071G >A polymorphism in codon 691 of the RET
proto-oncogene that was not mutated.
During the follow-up calcitonin (basal and after
pentagastrin stimulation) and CEA were in the normal
range until September 2008, when basal calcitonin
started to slightly increase (up to 64 pg/ml). Neck ultra-
sound was negative, but contrast-enhanced computed
tomography scan (CT-scan) showed diffused lung microno-
dules. Then, the 99mTc-MDP bone scan showed an uptake
area at the pedicle and right lamina of the fifth lumbar
vertebra (November 2009) and 18-Fluorodeoxyglucose
Positron Emission Tomography (18FDG-PET) and 68Ga-
DOTATOC-PET confirmed the fifth lumbar vertebra asthe only metastatic site. In 2011, the disease progressed
(at bone scan the known uptake area enlarged and a
new pathologic area appeared in the right hemisacrum).
Bone lesions were osteoblastic on X-ray evaluation.
Lung metastases remained stable in the absence of new
lesions at CT-scan. Serum calcitonin and CEA levels
were 141 pg/ml and 21 ng/ml, respectively. The patient
was still asymptomatic.
In March 2012, the patient presented with a painless
nodule in the right testis and a palpable right inguinal
lymph node. Ultrasound showed an hypoechoic and inho-
mogenous solid mass of 17 mm in size in the upper lobe of
the right testis and a 2 cm inguinal lymph node (Figure 1).
β-human chorionic gonadotropin (β-HCG), α-fetoprotein
and lactate dehydrogenase were normal. Calcitonin was
175 pg/ml, CEA 22 ng/ml. CT-scan showed a slight in-
crease in two lung nodules (each 1 cm in diameter).
Given that primary testicular cancer was suspected,
the patient underwent right radical orchiectomy and ex-
cision of the inguinal lymph node. Histology revealed
the presence of metastases, morphologically resembling
MTC, both in the testis (2.2 cm in diameter) where
tumor cells infiltrated the rete testis, and in the inguinal
lymph node. Immunohistochemistry showed reactivity
for AE1/AE3, TTF-1 calcitonin and chromogranin, but
not for CD30, actin-μ and vimentin, thus confirming the
diagnosis of metastases from MTC (Figure 2).
Post-surgery calcitonin and CEA levels decreased, but
did not normalize. Recently, progressive disease was
documented in the lung, bone and inguinal lymph
nodes. The patient is still asymptomatic, but is going
to start vandetanib.
Discussion
Testicular metastases are extremely rare, except in pa-
tients affected by leukemia or lymphoma [17]. Metastases
to the testis from solid tumors may be discovered inci-
dentally at autopsy or following therapeutic/diagnostic
orchiectomy, as in the case presented. In autopsy series
that included non-neoplastic deaths, testicular metasta-
ses were found in 0.02% to 2.5% of specimens [17-21].
In other series of patients who underwent orchiectomy
for testicular malignancy, testicular metastases were
detected in up to 7% of patients, the common primary
malignancy being prostate, melanoma, sarcoma, lung,
urologic and gastrointestinal cancer (Table 1) [22-27].
Less frequently urinary bladder and pancreatic tumors
or neuroblastoma metastasize to the testis [28]. Bilateral
involvement of the testis occurs in about 15% of cases
[17-27]. Involvement of the testis is usually accompan-
ied by cancer spreading to other sites, rarely affecting
survival that remains largely dependent on the burden
and aggressiveness of the underlying disease and the
vital importance of involved organs. Surgery, if indicated,
Figure 1 Ultrasound images show a solid and inhomogeneous hypoechoic mass in the upper lobe of the right testis (A) and a right
inguinal lymphoadenopathy 2 cm in diameter (B).
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malignancies. Testicular metastasis from MTC has never
been reported.
The mechanisms of metastatic spread to the testis is
still speculative. It has been suggested that metastases
from solid tumors might join testis via retrograde arter-
ial, venous or lymphatic embolization [29]. SpecificFigure 2 Histological and immunohistochemical examinations. A, B: His
thyroid carcinoma in the right inguinal lymph node; D: The right testis: histolo
cells of medullary thyroid carcinoma, partially separated by fibrous stroma infi
diffuse cytoplasmic positivity for TTF-1 (E) and with calcitonin (F).spreading routes have been associated with certain solid
tumors, including arterial embolism from lung cancer
[30], retrograde venous spread in renal cell carcinoma
[29] or retrograde lymphatic spread in gastrointestinal,
prostate and urinary bladder cancer [28,29,31]. In an
anatomic study of spermatic veins, Wishami et al. dem-
onstrated connections between spermatic and renaltology of primary medullary thyroid cancer; C: Metastasis of medullary
gical examination shows trabecular solid areas with round and spindle
ltrating testicular parenchyma. Immunohistochemistry: Tumor cells show





N. of patients with
testicular metastases (%)
Primary solid tumors (%)
Pienkos et al. [20] Autopsy 24,000 15 (0.06) Lung 7 (46.6); Melanoma 2 (13.2);
Ureter 1 (6.7); Kidney 1 (6.7); Rectum
1 (6.7); Salivary gland 1 (6.7); Pancreas
1 (6.7); Unknown 1 (6.7).
Nistal et al. [28] Autopsy 3,474 5 (0.14) Pancreatic 1 (20); urinary bladder 1
(20); prostate 1 (20); neuroblastoma
2 (40).
Tiltman AJ. [18] Autopsy 2,271 6 (2.5) Prostate 2 (33.3); melanoma 2 (33.3);
lung 1 (16.7); pleural mesothelioma
1 (16.7)
García-González et al. [21] Autopsy 780 5 (0.64) Lung 3 (60); melanoma 1 (20);
pancreatic endocrine carcinoma 1
(20).
Patel et al. [23] Autopsy/diagnostic/therapeutic 550 20 (3.6) Prostate 12 (60), melanoma 3 (15),
sarcoma 2 (10), lung 1 (5), colon 1
(5), renal carcinoma 1 (5)
Sharma et al. [25] Diagnostic/therapeutic 300 10 (3.33) Prostate 6 (60); lung 1 (10); larynx 1
(10); kidney 1 (10); colon (10).
Lu et al. [26] Diagnostic 200 14 (7) Prostate 8 (57.1); Lung 2 (14.3);
Esophagus 1 (7.1); Seminal
vescicles 1 (7.1); Sigmoid colon
1 (7.1); Unknown 1 (7.1).
Dutt et al. [19] Autopsy/diagnostic/therapeutic 31 22 Prostate 6 (27.4); stomach 5 (22.8);
lung 3 (13.6); melanoma 2 (9.2);
neuroblastoma 1 (4.5), medulloblastoma
1 (4.5); rectum 1 (4.5); rhabdomyosarcoma
1 (4.5); pancreas 1 (4.5); unknown (4.5)
(leukemias: 9 cases).
Ulbright et al. [27] Diagnostic 26 26 Prostate 11 (42.3); renal 4 (15.4); colon
4 (15.4); urinary tract 3 (11.5); lung 2
(7.7); esophagus 1 (3.8); small intestine
1 (3.9).
Grignon et al. [22] Diagnostic/autopsy 18 18 Lung 9 (50), prostate 4 (22.2), stomach
4 (22.2), bile tract 1 (5.6).
Bhasin et al. [24] Diagnostic/therapeutic 10 10 Prostate 4 (40); gastrointestinal 4 (40);
kidney 2 (20).
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lonic veins. These findings may sustain the retrograde
venous spread from both kidney and colon cancer [32].
Moreover, the absence of valves in spermatic veins has
been suggested as a favoring factor for the retrograde
spread from the renal veins or the retroperitoneum [31].
Metastases from prostatic carcinoma and seminal vesicle
cancer may reach testis via direct extension and intra-
ductal spread via the vas deferens and epididymis
[22,23].
In patients presenting a solitary testicular mass, the
differential diagnosis must include metastatic carcinoma.
A personal history of cancer should first be investigated.
Older age is suggestive of a secondary testicular tumor.
Measurement of serum α-fetoprotein and β-HCG, if
negative, does not exclude a testicular primary germ cell
tumor. However, post-surgery/-biopsy histopathologyevaluation is almost invariably required to address the
differential diagnosis of a testicular mass [33].
Histology features of testicular metastases are quite
different from primary tumors of the testis. The former
present as a nodule of small nests of tumor cells more
commonly located in the epididymis and para-
epididymal area, with a widespread involvement in the
interstitium and the relative sparing of the seminiferous
tubules [17]. Interstitial cell tumors or early invasive
seminoma may present similar features [17]. However,
the absence of seminiferous tubular involvement is a dis-
tinguishing aspect of metastatic lesions [17,23]. Exten-
sive vascular and lymphatic invasion of parenchyma
and tunica albuginea, multifocality or bilaterality are
also features suggestive of metastases from solid ma-
lignancies. The immunostaining positivity for epithe-
lial membrane antigen (EMA) and placental alkaline
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tumor [26]. Similarly, the absence of EMA-positive
immature testicular germ cells are also features favor-
ing metastasis rather than primary testicular tumors
[26].
Even though, the rarity of metastatic involvement of
testis remains unexplained, it may be due to blood-testis
and blood-epididymis barrier [34,35]. The tight junctions
between Sertoli cells and between epididymis epithelial
cells respectively, build a functional barrier of utmost
competence [36]. These barriers create a unique anatom-
ical, physiological and immunological microenvironment
that restrict the passage of molecules and cells from enter-
ing or exiting the lumen [35,36]. This condition allows the
proper development of the germ cells into fully functional
sperm, most likely limiting metastatic deposits as well
[35,36]. It has also been suggested that low temperature
in the scrotum creates an unfavorable environment for
the seeding of metastases [17,34-37]. However, molecu-
lar mechanisms allowing the blood-testis and blood-
epididymis barriers to prevent metastatic spread to
testis and how metastases overcome these protective
mechanisms remain still unclear.
Inguinal lymph nodes are not a known site of metastatic
spread from MTC. Metastases to inguinal lymph nodes
are more commonly involved by cells from lymphoma
and other malignant tumors located in the skin of lower
extremities, in the scrotum, penis, vulva, clitoris, lower
third of the vagina, anal canal, and infraumbilical region
of the anterior abdominal wall. Melanoma or squamous
cell carcinoma arising on the skin of the trunk may also
metastasize to the inguinal lymph nodes. Rarely prostate,
testicular or colon primary malignancies metastasize to
inguinal lymph nodes [38,39]. When this happens, pre-
vious inguinal, pelvic or scrotal surgery may have
altered lymphatic drainage [40]. Injured lymphatics
may harbor new anastomoses between testicular and
inguinal/pelvic lymphatic plexes, providing a potential
direct way of metastatic spread to the inguinal lymph
nodes [41]. Alternatively, the involvement of the adja-
cent anterior abdominal wall by micrometastasis or
preexisting aberrant lymphatic drainage route have been
postulated [41].
It is presumable that MTC metastases reached the
testis first and then the inguinal lymph node via the
infiltration of the rete testis. However, it is impossible to
establish whether metastatic spread occurred vice versa
or simultaneously.
Another interesting aspect of the present case, lies in
the unexpectedly low levels of serum calcitonin and
CEA in relation to the widespread dissemination of the
disease. Calcitonin is a specific serum marker of MTC
[1]. Preoperative calcitonin levels are very useful for both
diagnosis and staging [1,2]. In case of nodalmetastases, basal calcitonin levels commonly range be-
tween 10-40 ng/ml (normal range, <10 ng/ml), whereas
distant metastases are usually associated with a calci-
tonin level >150 ng/ml and often >1000 ng/ml [6,16].
Moreover, CEA may be increased in more than 50% of
MTC patients and may be useful especially when pre-
operative calcitonin is within normal range [16]. A pre-
operative CEA serum level >30 ng/ml predicts poor
prognosis and indicates that surgery may not be cura-
tive. CEA levels >100 ng/ml suggest extensive lymph
node involvement and distant metastases. Increasing
CEA levels with stable calcitonin suggest tumor dedif-
ferentiation and worse prognosis [6,16]. Serum calci-
tonin and CEA measurements 2-6 months after the
surgery are recommended to detect residual disease.
Patients with undetectable serum calcitonin (basal and
after stimulation test) and normal CEA values are vir-
tually cured, being approximately 3-5% their 5-year recur-
rence rate [6,13]. High basal serum calcitonin values
≥6 months after surgery are suggestive of residual disease.
Moreover, calcitonin and CEA doubling times strongly
predict disease progression and reduced survival [42,43].
In our opinion, the low serum levels of calcitonin and
CEA (175 pg/ml and 22 ng/ml, respectively), despite lung,
bone, testicular and inguinal lymph node metastases, are
consistent with the low aggressiveness and the smoldering
progression of the disease. These biological features may
be not rarely seen in patients with MTC.
Conclusions
To the best of our knowledge, this is the first case report
on testicular metastasis of MTC. Also inguinal lymph
node involvement as a site of relapsing MTC has never
been described before. In this patient, MTC metastases
to the testis and inguinal lymph node were associated
with disseminated disease, which is commonly observed
in testicular metastases from solid malignancies. The
present report, beyond its rarity, emphasizes that physi-
cians need to consider testis and inguinal lymph nodes as
an unusual, but possible site of metastases from MTC,
even in the presence of relatively low serum markers of
malignancy.
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